Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

ConferenceSER-603Positive

AI Analysis

Summary

Seres Therapeutics presented preclinical data for SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease, at Digestive Disease Week 2026, highlighting rational design targeting mucosal healing and advancement of microbiome-based biomarkers for patient stratification.

Outcome Details

Preclinical data presented at Digestive Disease Week 2026 supporting SER-603's rational design targeting microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD; advancement of microbiome-based biomarkers for patient stratification

Importance:4/10

Sentiment:

0.50

preclinicalIBDlive biotherapeuticmicrobiomebiomarkersconference presentation

Related Companies

$MCRB $DSGN

Read the original article

Published by GlobeNewswire Clinical Studies on May 4, 2026 11:00 AM

Read Original